Story perspectives

Iovance’s Phase 2 Lung Cancer Trial Shows 24.6% Response

By Drooid · Oct 29, 2026 · How we work

Read the story

Story summary

Summary

Iovance Biotherapeutics reported a 24.6% objective response rate in its Phase 2 IOV-LUN-202 lung cancer trial.
The trial enrolled 69 previously treated non-squamous NSCLC patients and recorded 17 responses, including 15 confirmed.
A biomarker-enriched subgroup of 22 KRAS-wild-type, HER2-wild-type smokers achieved a 59.1% response rate.
IOV A shares rose about 12% in after-hours trading on October 28 after the data release.

1 of 1

Iovance Biotherapeutics reported a 24.6% objective response rate in its Phase 2 IOV-LUN-202 lung cancer trial.
The trial enrolled 69 previously treated non-squamous NSCLC patients and recorded 17 responses, including 15 confirmed.
A biomarker-enriched subgroup of 22 KRAS-wild-type, HER2-wild-type smokers achieved a 59.1% response rate.
IOV A shares rose about 12% in after-hours trading on October 28 after the data release.